Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)
(Real Time Quote from BATS)
$1.36 USD
-0.02 (-1.45%)
Updated Aug 6, 2025 03:56 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Barinthus Biotherapeutics PLC Sponsored ADR's dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
BRNS 1.36 -0.02(-1.45%)
Will BRNS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BRNS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BRNS
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why
BRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BRNS
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
US Stocks Mixed; Bank of America Earnings Top Views
Barinthus Biotherapeutics Approves Key Proposals at AGM
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June ...